Payment overview · 2025
General Payments
$5,576.71
217 reported records · 34 companies
Healthcare provider profile · identity verified
Luis E Rojas, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BRIDGEPORT, CT · NPI 1487785838
Verified facts
What the public records show
CMS Open Payments records show Luis E Rojas, APRN received $5,576.71 in general payments during 2025 across 217 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $698.39 | 12.5% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $691.56 | 12.4% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $459.51 | 8.2% | 17 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $310.32 | 5.6% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $287.31 | 5.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $285.04 | 5.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $252.22 | 4.5% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $239.25 | 4.3% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $216.59 | 3.9% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $198.51 | 3.6% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $160.10 | 2.9% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $158.14 | 2.8% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.67 | 2.8% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $153.72 | 2.8% | 15 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $153.58 | 2.8% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.55 | 2.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $144.49 | 2.6% | 6 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $142.92 | 2.6% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $88.71 | 1.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.26 | 1.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.27 | 1.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.66 | 1.3% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $59.58 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.72 | 0.9% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $46.26 | 0.8% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $45.64 | 0.8% | 3 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $37.77 | 0.7% | 2 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $33.03 | 0.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.64 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.76 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.32 | 0.4% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.46 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.34 | 0.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $15.42 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,572.50 | 216 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $531.64 | 20 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $353.56 | 16 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $348.18 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $319.85 | 15 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $310.32 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $288.61 | 14 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $287.31 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $239.25 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $239.08 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $216.59 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $204.00 | 15 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $198.51 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.12 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $160.10 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $158.14 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $156.67 | 8 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $153.58 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $138.82 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $138.82 | 7 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $123.80 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $120.49 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.40 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.41 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $76.27 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $76.27 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $74.66 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $59.58 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $56.95 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $45.64 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.45 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $33.03 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $25.95 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 143 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 51 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 74 |
| Losartan Potassium | Losartan Potassium | 218 | 72 |
| Gabapentin | Gabapentin | 203 | 63 |
| Metformin Hcl | Metformin Hcl | 191 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 68 |
| Omeprazole | Omeprazole | 175 | 57 |
| Lisinopril | Lisinopril | 163 | 61 |
| Linzess | Linaclotide | 143 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 35 |
| Jardiance | Empagliflozin | 127 | 31 |
| Montelukast Sodium | Montelukast Sodium | 104 | 35 |
| Ozempic | Semaglutide | 103 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 33 |
| Famotidine | Famotidine | 86 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 20 |
| Meclizine Hcl | Meclizine Hcl | 72 | 20 |
| Farxiga | Dapagliflozin Propanediol | 70 | 22 |
| Valsartan | Valsartan | 64 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 25 |
| Clotrimazole | Clotrimazole | 54 | 25 |
| Meloxicam | Meloxicam | 52 | 22 |
| Rybelsus | Semaglutide | 51 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 47 | 12 |
| Simvastatin | Simvastatin | 47 | suppressed |
| Ztlido | Lidocaine | 47 | 16 |
| Ammonium Lactate | Ammonium Lactate | 45 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 15 |
| Furosemide | Furosemide | 43 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 13 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 34 | 14 |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Atenolol | Atenolol | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Terconazole | Terconazole | 19 | 11 |
| Alprazolam | Alprazolam | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Nystatin | Nystatin | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,576.71 · 217 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AMVUTTRA, AREXVY, BREZTRI, CABENUVA, CAMZYOS, COBENFY, DOVATO, ELIQUIS, ENTRESTO, FARXIGA, FFRct, FREESTYLE LIBRE 3, FUROSCIX, GLYCATE, GVOKE HYPOPEN, IBSRELA, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, Linzess, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, ONPATTRO, OTEZLA, OtoSight Middle Ear Scope, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZTLido | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error